Ardelyx, Inc.
NASDAQ:ARDXBiotechnology
-$0.06 today
- Market cap
- $784.28M
- Beta
- 0.58
- P/E (TTM)
- -24.5
- EPS (TTM)
- -$0.24
Volume 4.75M
Average 3.58M
ARDX Total Current Liabilities
All obligations due within one year.
Ardelyx, Inc.NASDAQ: ARDX
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 44.5% from a year ago
Total current liabilities stood at $109.57M at the end of Q1 FY2026, up 44.5% from a year earlier and up 23.7% from the prior quarter. Over 3 fiscal years it compounded at +10.5% a year.
Context
- Total current liabilities amounted to 21.7% of total assets at the end of Q1 FY2026, up 3.2 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +44.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 88.61M USD
- Year-over-year change
- +13.8%
- 4-year CAGR
- +13.8%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 88.61M | +13.8% |
| FY2024 | 2024-12-31 | 77.83M | +54.4% |
| FY2023 | 2023-12-31 | 50.39M | -23.2% |
| FY2022 | 2022-12-31 | 65.6M | +24.2% |
| FY2021 | 2021-12-31 | 52.82M | — |
Total Current Liabilities vs competitors
How ARDX compares with its peers on the latest reported figures
- ARDX's Mar 2026 total current liabilities of $109.57M is the 3rd highest of the 5 companies compared; the peer median is $69.91M.
- Its year-over-year change of +44.5% is the 2nd highest of 5, against a peer median of +24.0%.
- Total current liabilities amounts to 21.7% of total assets for ARDX, versus a peer median of 20.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $173.88M | +90.6% | +7.9% | 48.0% | |
| Mar 2026 | $118.59M | +24.7% | +14.2% | 30.3% | |
| Mar 2026 | $109.57M | +44.5% | +10.5% | 21.7% | |
| Mar 2026 | $21.24M | +14.1% | +2.8% | 5.1% | |
| Mar 2026 | $5.75M | +23.2% | +33.3% | 10.8% | |
| Peer median (excluding ARDX) | $69.91M | +24.0% | +11.1% | 20.5% | |
Competitors are the stored peer set for ARDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 72.43M | 96.14M | 21.47M | 64.93M | 68M |
| Short-term Investments | 44.26M | 27.77M | 162.83M | 185.17M | 196.69M |
| Net Receivables | 502K | 7.73M | 22.03M | 57.71M | 71.85M |
| Inventory | 0 | 3.28M | 12.45M | 21.17M | 17.74M |
| Other Current Assets | 1 | 5.11M | 8.41M | 11.1M | 13.57M |
| Total Current Assets | 133.65M | 153.6M | 246.11M | 356.45M | 382.32M |
| Property, Plant & Equipment (Net) | 15.11M | 10.52M | 6.6M | 3.88M | 6.98M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.15M | 25.95M | 44.87M | 75.43M | 112.31M |
| Total Non-current Assets | 16.26M | 36.46M | 51.47M | 79.3M | 119.29M |
| Total Assets | 149.91M | 190.07M | 297.58M | 435.75M | 501.6M |
| Account Payables | 4.28M | 10.86M | 11.14M | 16M | 19.24M |
| Short-term Debt | 32.26M | 26.71M | 0 | 0 | 1.48M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 4.21M | 7.18M | 10.69M | 1.21M |
| Other Current Liabilities | 1.24M | 10.09M | 15.04M | 21.48M | 66.69M |
| Total Current Liabilities | 52.82M | 65.6M | 50.39M | 77.83M | 88.61M |
| Long-term Debt | 0 | 0 | 49.82M | 150.85M | 206.48M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 9.03M | 8.64M | 7.23M | 39.58M |
| Other Non-current Liabilities | 4.73M | 11.25M | 20.18M | 25.53M | (3.64M) |
| Total Non-current Liabilities | 14.48M | 26.13M | 80.37M | 184.64M | 246.05M |
| Total Liabilities | 67.3M | 91.74M | 130.76M | 262.47M | 334.66M |
| Common Stock | 13K | 20K | 23K | 24K | 24K |
| Retained Earnings | (712.93M) | (780.14M) | (846.2M) | (885.34M) | (946.94M) |
| Accumulated OCI | (6K) | (54K) | 224K | 57K | 198K |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 82.62M | 98.33M | 166.82M | 173.29M | 166.95M |
| Total Debt | 45.5M | 36.46M | 55.98M | 153.44M | 211.6M |
| Net Debt | (26.92M) | (59.68M) | 34.51M | 88.51M | 143.6M |
Ardelyx, Inc.
NASDAQ:ARDX
Intrinsic Alpha fair value
Locked
Current Price
$3.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.